Evidence map›Paper›PMID 32900685›Full record

ArticleAntimicrobial agents and chemotherapy2020

Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an

Shuhei Matsumoto, Sachi Kanazawa, Takafumi Sato, Yoshinori Yamano

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Antimicrobial agents and chemotherapy · 2023
    Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shuhei MatsumotoBusiness Development, Shionogi & Co., Ltd., Osaka, Japan shuuhei.matsumoto@shionogi.co.jp.ORCID 0000-0003-0377-8304
Sachi KanazawaDrug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan.
Takafumi SatoDrug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan.
Yoshinori YamanoDrug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan.
Shionogi (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activities of cefiderocol under simulated human plasma concentrations at the recommended dosing regimen of 2 g every 8 h with a 3-h infusion were evaluated using an

Indexed as

CarbapenemsDrug Resistance, Multiple, BacterialAnti-Bacterial AgentsCefiderocolCephalosporinsGram-Negative BacteriaHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsCarbapenemsCefiderocolCephalosporinsAcinetobacter baumanniicarbapenem resistantcefiderocolchemostat modelEnterobacteralesnonfermenters

Identifiers

PMID32900685
PMCPMC7577172
OpenAlexW3083632680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.